Pfizer Prevnar vaccine wins approval for ages 6-17

Sat Jan 26, 2013 3:41am IST

Related Topics

Stocks

   

(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.

The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.

The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.

Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.

(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

EBOLA OUTBREAK

REUTERS SHOWCASE

Change Of Venue

Change Of Venue

Parks, playgrounds offer fresh air alternatives to gym workouts.  Full Article 

Antibiotics Quest

Antibiotics Quest

Extreme medicine: The search for new antibiotics.  Full Article 

Biotech Drugs

Biotech Drugs

'Plantibodies' drugs advance as big pharma stands aside.  Full Article 

Promising Vaccine

Promising Vaccine

Experimental chikungunya vaccine shows promise in human trial.  Full Article 

No Unanimity

No Unanimity

Even dentists differ on the best tooth-brushing method.  Full Article 

Importance Of Religion

Importance Of Religion

Religiosity associated with less depression in elderly: study.  Full Article 

Changing Demographic

Changing Demographic

From cradle to grave, Japan's Kewpie adapts menu to feed ageing nation.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage